Proteolytic release from the cell surface is an essential activation event for many growth factors and cytokines. TNF-α converting enzyme (TACE) is a membrane-bound metalloprotease responsible for solubilizing many pathologically significant membrane substrates and is an attractive therapeutic target for the treatment of cancer and arthritis. Prior attempts to antagonize cell-surface TACE activity have focused on small-molecule inhibition of the metalloprotease active site. Given the highly conserved nature of metalloprotease active sites, this paradigm has failed to produce a truly specific TACE inhibitor and continues to obstruct the clinical investigation of TACE activity. We report the bespoke development of a specific TACE inhibitory human antibody using "two-step" phage display. This approach combines calculated selection conditions with antibody variable-domain exchange to direct individual antibody variable domains to desired epitopes. The resulting "cross-domain" human antibody is a previously undescribed selective TACE antagonist and provides a unique alternative to smallmolecule metalloprotease inhibition.
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ADAM17 | antibody phage display | cancer therapeutics T NF-α converting enzyme (TACE) [a disintegrin and metalloprotease 17 (ADAM17)], is a membrane-bound metalloprotease responsible for cleaving a variety of pathologically significant substrates (1) . Initially identified as the enzyme responsible for solubilizing membrane-associated pro-TNF-α (2, 3)-a process subsequently termed "ectodomain shedding," TACE has since proved capable of cleaving epidermal growth factor receptor (EGFR) ligands (4), extracellular Notch1 (5), cell-surface receptors (6) , and adhesion molecules (7) . As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer (8) and rheumatoid arthritis (9) .
Preceding the current clinical interest in TACE, members of the related matrix metalloprotease (MMP) family were also considered viable therapeutic targets (10) . Despite sound preclinical rational for antagonizing MMPs, early trials of smallmolecule inhibitors (SMIs) failed due to poor inhibitor specificity profiles (11, 12) . Metalloprotease SMIs exclusively target the catalytic site. This paradigm treats the raw proteolytic capacity of the catalytic site as the only significant target-often with no regard to noncatalytic domains. This catalytic focus forces the selectivity of SMIs to rely exclusively on modest biophysical differences surrounding individual metalloprotease catalytic sites and typically yields inhibitors simply with a bias toward a particular metalloprotease. Macromolecular metalloprotease inhibitors [e.g., tissue inhibitor of metalloproteases (TIMPs) and metalloprotease prodomains] also focus on binding the catalytic site and suffer comparable specificity limitations. The unfortunate simplification of multidomain extracellular proteases to spatially isolated catalytic sites has ignored the potential for noncatalytic residues to contribute toward inhibitor specificity. A broader multidomain TACE antagonist would provide an attractive alternative to the SMI paradigm.
Mature ADAM-family ectodomains contain a globular metalloprotease catalytic domain, a disulphide-dependent disintegrincysteine rich (Dis-Cys) domain, and, in some cases, an epidermal growth factor (EGF)-like domain. Although most ADAM catalytic domains appear to share homologous structural topology, significant sequence variation is common throughout the noncatalytic Dis-Cys domains [especially in the "hyper-variable" region (HVR)] (13). Despite their divergent nomenclature, accumulating evidence suggests the catalytic domain and Dis-Cys domain are spatially associated within the complete ADAM ectodomain (14, 15) . Specifically, the crystal structures of ADAM homologs VAP1 (13), VAP2B (16) , RVVX (17) , and the nonproteolytic ectodomain of human ADAM22 (18) support the notion that ADAM proteins are "C-shaped" (Fig. S1 ). This model implies the TACE noncatalytic carboxyl-terminal Dis-Cys domain partially obstructs macromolecular access to the amino-terminal catalytic domain. As a result, large catalytic-cleft inhibitors such as TIMPs (14) and ADAM prodomains (19) fail to bind complete ADAM ectodomains efficiently. To overcome this issue, we proposed that a selective ADAM inhibitor could instead utilize this spatially connected C-shaped multidomain topology by broadly antagonizing the catalytic domain while simultaneously sourcing additional specificity from local noncatalytic Dis-Cys residues.
Antibody phage display is an established technology for producing inhibitors against complex extracellular proteins (20) . As solution-phase phage display typically produces antibodies with conformational (i.e., nonlinear) epitopes, this technology is also theoretically capable of providing the intricate macromolecular cross-domain binding desirable in an ADAM inhibitor. Recent technical advances in phage display have produced antibodies recognizing multiple disparate antigens (21) and different conformations of the same antigen (22, 23) . These approaches use a combination of calculated selection conditions and/or antibody variable-domain chain-shuffling to produce antibodies against previously unique epitopes. We hypothesized that similar techniques could be employed to achieve multidomain protease inhibition.
We exploited ADAM multidomain topology by first isolating an inhibitory human antibody (D1) that bound TACE-specific noncatalytic regions exclusively through its variable heavy (V H ) domain. We then used a D1-V H biased scFv phage-display library to selectively isolate a new variable light (V L ) chain that could simultaneously bind to the TACE catalytic domain (Fig. 1) . The resulting "cross-domain" human antibody [D1(A12)] is a previously undescribed biochemically holistic ADAM ectodomain inhibitor and demonstrates a unique alternative to smallmolecule metalloprotease inhibition.
Results
Isolation of an Anti-TACE Ectodomain Inhibitory Human Antibody.
While most TACE drug discovery projects focus on inhibiting the proteolytic capacity of the isolated catalytic domain, we purposefully chose to antagonize the complete ectodomain. In light of both recent structural advances and prior biochemical observations, we hypothesized that selectively targeting noncatalytic regions of the complete TACE ectodomain would produce a more specific cell-surface inhibitor. To this end, recombinant human TACE ectodomain was biotinylated, checked for wildtype activity, and exposed to a naïve human scFv antibody phagedisplay library (24) for two rounds of solution-phase selections. As previous attempts to directly target metalloprotease catalytic sites have resulted in unwanted cross-reactivity (e.g., TIMPs, ADAM prodomains, and SMIs), we blocked the TACE catalytic cleft with the broad-spectrum metalloprotease inhibitor CT1746 (25) during initial selections (Fig. 1) . The resulting TACE ectodomain antigen could therefore not select for antibodies with epitopes dependent on residues deep within the catalytic site. Following ELISA screening (Fig. S2A) , subsequent positive scFv His-tagged clones were sequenced to remove replicates, expressed in Escherichia coli and affinity-purified [immobilized metal affinity chromatography (IMAC)] for functional characterization. Although several inhibitory antibodies were identified by their ability to hinder TACE quenched-fluorescent (QF) peptide proteolysis (Fig. S2C) , only scFv D1 retained this inhibitory profile when tested against cell-surface shedding of HB-EGF (Fig. S2D) . ScFv D1 inhibited TACE ectodomain activity with comparable potency to the amino-terminal domain of the natural TACE inhibitor TIMP-3, N-TIMP-3, in both QF-peptide ( Fig. 2A) and HB-EGF shedding assays (Table S2 ). However, unlike N-TIMP-3, scFv D1 did not bind the isolated catalytic domain of TACE (Fig. 2B) . We have previously shown that protein disulphide isomerase (PDI) can alter the three-dimensional topology of the TACE Dis-Cys domain (26) . In a similar fashion to the Dis-Cys binding scFv D3, PDI modulation of the TACE ectodomain seriously disrupted scFv D1 immunoreactivity (Fig. 3B ). When combined with the lack of isolated catalytic domain binding, this observation suggests scFv D1 primarily bound the noncatalytic TACE Dis-Cys domain. Alanine-scanning mutagenesis of individual scFv D1 complementarity determining region (CDR) loops revealed that residues in the V H chain of scFv D1 were primarily responsible for TACE ectodomain binding. In contrast, the CDR loops of the V L domain did not appear to significantly contribute toward the active D1 paratope (Fig. 2C ). This may explain the modest affinity of scFv D1 (K D ¼ 26ðAE2.2Þ nM) for the TACE ectodomain (Table 1 and Fig. S3 ). Despite this conservative paratope, scFv D1 appeared to be entirely selective for human TACE ( Fig. 2D and Fig. S4 ). Collectively, we conclude scFv D1 is a selective V H -dependent inhibitory antibody that primarily binds to the noncatalytic TACE Dis-Cys domain. (39) . We exploited this multidomain topology to develop a truly specific ADAM inhibitor using two-step antibody phage display. (B) (i) First, the catalytic site of TACE ectodomain was blocked during primary antibody phage-display selections using the small-molecule inhibitor CT1746. This prevented the selection of antibodies with catalytic-cleft epitopes that could cross-react with nontarget metalloproteases. (ii) Primary screening revealed the inhibitory scFv antibody clone D1. This scFv bound specifically to the TACE Dis-Cys domain through its variable heavy (V H ) domain. (iii) A D1-V H -bias antibody phagedisplay library was produced to introduce new variable light (neo-V L ) chains while maintaining the TACE specificity provided by the D1-V H . Secondary selections were performed in the absence of CT1746 in order to provide the neo-V L chains with uninterrupted access to the TACE catalytic site. (iv) Secondary screening identified several neo-V L scFvs capable of binding the isolated TACE catalytic domain. Due to Dis-Cys domain binding through the D1-V H these "cross-domain" antibodies maintained their strict specificity for TACE. D1-V H -neo-V L scFv clone A12 (D1(A12)) exhibited the highest affinity for the TACE ectodomain and is the most selectively potent cell-surface ADAM inhibitor ever described. Introduction of Catalytic Domain Binding by V L -Exchange. While scFv D1 selectively inhibited TACE ectodomain activity with comparable potency to the broad metalloprotease inhibitor TIMP-3, its limited paratope, poor affinity, and lack of catalytic domain binding suggested the antagonist could be improved. As scFv D1 bound noncatalytic regions through its V H domain, yet was close enough to the catalytic site to block small peptide hydrolysis, we hypothesized that the currently quiescent V L domain was in close proximity to the TACE catalytic domain. We subsequently hypothesized that the nonfunctional D1 V L -CDRs could be engineered to introduce TACE catalytic domain binding. To explore this idea, the D1-V H domain was cloned into a naïve human V L phage-display library and the resulting "D1-V H -neo-V L library" was stringently reselected against titrated concentrations of biotinylated TACE ectodomain. As the D1-V H was already entirely TACE selective through Dis-Cys binding ( Fig. 2D and Fig. S4 ), we removed CT1746 from all D1-V H -neo-V L selections to provide neo-V L domains with uninterrupted access to the TACE catalytic site. The resulting selection scenario encouraged all D1-V H -neo-V L scFvs to maintain TACE selectivity (by binding to ectodomain Dis-Cys regions through the D1-V H ) while simultaneously exposing neo-V L domains to a previously inaccessible catalytic-cleft epitope (due to the absence of the small-molecule antagonist) (Fig. 1B) .
Following two rounds of both solution and solid-phase selections, 1,200 D1-V H -neo-V L scFvs were rescreened for both TACE ectodomain and isolated catalytic domain binding. The best 30 TACE ectodomain-binding clones were isolated, sequenced to remove replicates, individually expressed in E. coli, and affinity-purified. D1-V H -neo-V L lead scFvs were then quantitatively ELISA screened for their capacity to bind both the complete TACE ectodomain and the isolated catalytic domain (Fig. 3A) . As predicted, stringent selection of neo-V L chains against TACE in the absence of CT1746 produced multiple D1-V H -neo-V L scFv variants now capable of independently binding the isolated TACE catalytic domain and the complete ectodomain. Lead scFv "A12" [hereafter D1(A12)] possessed the highest affinity for both antigens and was advanced for further analysis.
Kinetic Characterization of the D1(A12)-TACE Interaction. Screening ELISAs implied that the D1-V H -neo-V L clone D1(A12) could independently bind both the complete TACE ectodomain and the isolated catalytic domain (Fig. 3A) . In addition, D1(A12) is largely resistant to PDI modulation of the TACE Dis-Cys domain when compared to the parental scFv D1 (Fig. 3B) . Collectively, these results suggest the D1(A12) epitope contains residues from both the TACE catalytic and Dis-Cys domains. To characterize the kinetics of both interactions, D1(A12) was reformatted to a monovalent human FAb, amine-coupled to a CM5 Biacore chip, and titrated concentrations of either the TACE ectodomain or isolated catalytic domain were injected. Surface plasmon resonance (SPR) revealed D1(A12) possessed an affinity constant (K D ) of 0.46ðAE0.7Þ nM for the complete TACE ectodomain, but only 5.21ðAE0.1Þ nM for the isolated catalytic domain (Table 1 and Fig. S3 ). In contrast, noninhibitory anti-TACE antibodies from the primary selection (catalytic domain antibody A9 and Dis-Cys antibody D3) exhibit domain-specific profiles. The catalytic-domain focused TACE inhibitor N-TIMP-3 displays a 30-fold affinity preference for the isolated catalytic domain (ΔK D ¼ 0.03). D1(A12) is therefore unique: an ADAM inhibitor that shows an affinity preference for the complete ectodomain over the isolated catalytic domain. Macromolecular anti-TACE probes were amine-coupled to a Biacore CM5 chip and titrated concentrations of either isolated TACE catalytic domain (Cat.) or complete ectodomain (Ecto.) were injected. SPR kinetic analysis revealed the catalytic-cleft-focused TACE inhibitor N-TIMP-3 possessed a 30-fold affinity preference for the TACE catalytic domain over the complete ectodomain. Antibodies produced from primary phage-display selections bind either the catalytic domain (A9) or the noncatalytic Dis-Cys domain (D1 and D3). In contrast, the D1-V H -neo-V L secondary selection antibody D1(A12) displays a 10-fold affinity preference for the complete TACE ectodomain. D1(A12) is therefore the first ADAM inhibitor to show an affinity preference for the complete ectodomain over the isolated catalytic domain. SPR plots are illustrated in Fig. S3 .
D1(A12) Paratope Scanning Mutagenesis. As the initial D1 scFv did not react with the TACE catalytic domain-yet catalytic domain binding was effectively introduced through neo-V L -exchange-we concluded that residues within the original D1-V H interacted with the TACE Dis-Cys and residues within the neo-A12-V L interacted with the catalytic domain. To comprehensively characterize the D1(A12) paratope, all residues extending beyond the β-carbon were individually mutated to alanine, expressed in E. coli, and IMAC-purified. Cat∶WT ¼ 2.3ðAE0.1Þ nM) using an identical procedure. Subsequent changes in Gibb's free energy (ΔΔG) were calculated (ΔΔG ¼ þRT lnðIC 50
Ala ∕IC 50 WT Þ) (27) for each mutant and antigen (n ¼ 62) (Fig. 4) . In agreement with CDR mutagenesis of scFv D1 (Fig. 2C) , many D1(A12) V H residues contribute to IC 50
Ecto∶WT . Interestingly, CDR-H1 residues SH31 and YH32, and CDR-H2 residue SH52 (Kabat numbering) appear to exclusively contribute to IC 50
Ecto∶WT and are almost entirely dispensable for achieving IC 50
Cat∶WT . Conversely, CDR-L1 residues QL27, SL28, and IL29, and CDR-L3 residues SL91 and FL92, only appear to contribute to IC 50
Cat∶WT and are almost entirely dispensable for achieving IC 50
Ecto∶WT . To complement this solution-phase analysis, solid-phase ELISA EC 50 ΔΔG values were also calculated for all paratope mutants (Fig. S5A) . SPR was not used to obtain kinetic data for all 62 interactions because TACE immobilization led to its denaturation (see SI Materials and Methods). Despite their disparate methodology, the solution and solid-phase D1(A12) paratope ΔΔG profiles are remarkably similar (Fig. S5B) When mapped onto D1(A12) Fv RosettaAntibody frameworks (28), residues displaying either antigen bias were shown to cluster at polar ends of the paratope. In addition, CDR-H3 represents a dually important intermediate region within the core of the paratope. Collectively, these data strongly suggest that D1(A12) exclusively interacts with TACE Dis-Cys domain through residues on the outskirts of the V H domain and exclusively interacts with the catalytic domain through select residues in the V L domain.
D1(A12) Potently Inhibits the Complete TACE Ectodomain. Monovalent D1(A12) FAb proved capable of inhibiting the proteolysis of a macromolecular GST-TNF-α substrate by both the TACE ectodomain and the isolated catalytic domain (Fig. 5A) . Correlating with previous affinity data, D1(A12) FAb inhibited TACE ectodomain activity more potently than isolated catalytic domain activity (IC 50
Ecto ¼ 73.9ðAE3.2Þ nM; IC 50 Cat ¼ 124.7ðAE6.2Þ nM). Moreover, the D1(A12) FAb retained this potent inhibitory capacity in comprehensive QF-peptide analysis (Fig. 5B) . D1 (A12) FAb inhibited the isolated TACE catalytic domain with similar potency to the natural leading TACE inhibitor N-TIMP-3 (ΔIC 50 ¼ IC 50
Cat∶N-TIMP-3 ∕IC 50 Cat∶D1ðA12Þ ¼ 1.35). However, when identical assays were performed with the complete TACE ectodomain, D1(A12) proved to be over fivefold better than N-TIMP-3 (ΔIC 50 ¼ IC 50
Ecto∶N-TIMP-3 ∕IC 50 Ecto∶D1ðA12Þ ¼ 5.75).
As the rationale for inhibiting the complete TACE ectodomain was to produce a superior cell-surface TACE inhibitor for clinical application, D1(A12) was reformatted to a human IgG1 format and compared to N-TIMP-3 in multiple cancer cell-based shedding assays (Fig. 5C ). The effect of D1(A12) IgG1 on the shedding of four separate TACE ligands was investigated across four human cancer cell lines. Interestingly, the QF-peptide TACE ectodomain inhibitory profiles of D1(A12) and N-TIMP-3 were repeated in all four cell-surface shedding assays. Irrespective of substrate, cell line, or TACE expression levels, D1(A12) human IgG1 routinely inhibited cell-surface TACE activity fivefold better than N-TIMP-3 (Table S3 ). Similar inhibitory profiles were obtained with the monovalent D1(A12) FAb (Fig. S6 )-suggesting only one variable domain per IgG was binding cell-surface TACE. ELISA, QF-peptide, and cell-surface shedding assays also confirm D1(A12) specifically targets TACE and not closely related proteases (Fig. S7) . As only the TACE ectodomain is present at the cell surface, this collective data comprehensively demonstrates the antagonistic value in specifically targeting the complete TACE ectodomain.
Discussion
Despite some progress in developing TACE inhibitors over the past decade (29) , attempts to inhibit TACE using a catalyticsite directed approach have largely produced semispecific antagonists. In this study we describe how combining calculated phage-display selection conditions with subsequent antibody variable-domain exchange can produce a selective inhibitor of the complete TACE ectodomain. This approach utilizes a twostep selection process to independently direct both heavy and light antibody variable chains toward desired epitopes. By exploiting biochemical knowledge of the complete extracellular antigen, the D1(A12) cross-domain antibody has solved the decadeold problem of how to inhibit an ADAM ectodomain more efficiently than the isolated catalytic domain (14, 19) . Moreover, the selective potency of D1(A12) seriously challenges the exist- Fig. 4 . D1(A12) paratope scanning mutagenesis. (A) All D1(A12) scFv paratope residues extending beyond the β-carbon were individually mutated to alanine, expressed in E. coli, and affinity-purified. The IC 50 for each mutant against both the complete TACE ectodomain (IC 50 Ecto ) and the isolated catalytic domain (IC 50 Cat ) were determined in solution by quenched-fluorescent peptide assay. The change in Gibb's free energy (ΔΔG) was calculated (ΔΔG ¼ þRT lnðIC 50
Ala ∕IC 50 WT Þ) for each mutant and antigen (n ¼ 62). While many mutations proved detrimental to the D1(A12) IC 50 WT for both antigens, several appeared to specifically alter binding to either the TACE ectodomain (*) or the catalytic domain ( †). When mapped onto D1(A12) Fv frameworks (28) (employing colors detailed on the right y-axis), residues displaying an antigen bias cluster at polar ends of the paratope (dashed white lines). Comparable results were determined by solid-phase titration ELISA (Fig. S5) .
ing biochemical paradigm of solely targeting metalloprotease catalytic sites.
Despite the unique antagonistic approach reported, the use of noncatalytic residues to increase protease inhibitor specificity is not new. Existing inhibitory antibodies against the serine protease MT-SP1 were isolated by competitively selecting for scFv in the presence of a macromolecular antigen antagonist (30) . This approach yielded a steric hindrance antibody antagonist (E2) that sourced antigen specificity through MT-SP1 noncatalytic surface loops and inhibited by binding the active site (31) . However, unlike D1(A12), the epitope of E2 resides within the single catalytic domain of the MT-SP1 antigen. Given the "C-shape" of ADAM ectodomains, mimicking this approach with an isolated ADAM catalytic domain antigen would likely produce an inhibitor that suffers from similar ectodomain affinity limitations as TIMPs (14) and ADAM prodomains (19) . We demonstrate how multiple selection conditions in combination with antibody variable-domain exchange can circumvent these issues to produce a selective antagonist against a complete ADAM ectodomain.
Further studies with serine proteases have shown that antibodies can operate as either substrate blocking (steric hindrance) or allosteric inhibitors (32) . Given that D1(A12) shares a partially overlapping TACE catalytic-cleft epitope with CT1746 and TIMP-3 (Fig. S8) , it is logical to presume that D1(A12) inhibits TACE proteolysis by simply blocking macromolecular substrate access to the catalytic site. However, as the catalytic TACE zinc ion is thought to undergo dynamic charge transitions mediated by noncatalytic regions (15) , D1(A12) could also allosterically disrupt crucial communication between distal protein sites by simultaneously binding both noncatalytic and catalytic regions of TACE. Monitoring TACE behavior in the presence of D1(A12) using stopped-flow X-ray spectroscopy could help distinguish between steric hindrance and allosteric inhibition models. Two-step phage display produced an antibody capable of binding to both the TACE ectodomain (step one) and isolated catalytic domain (step two). Since recombinant TACE ectodomain immunoreactivity can be compromised by disulphide rearrangement (26) and TACE mutants often do not mature correctly (33), we focused on comprehensively characterizing the antibody paratope instead of the TACE epitope. Paratope scanning mutagenesis of D1(A12) described how D1-V H residues SH31, YH32, and SH52 are involved in binding the TACE ectodomain but appear dispensable for binding the isolated catalytic domain. These key residues may provide D1(A12) with its greater than 10-fold affinity preference for the TACE ectodomain over the catalytic domain. In contrast, A12-V L residues QL27, SL28, IL29, SL91, and FL92 primarily support binding to the isolated catalytic domain. Given that D1(A12) CDR-H3 remains unchanged from the original scFv D1 (noncatalytic binding), it is interesting that these residues play such an important role in binding the isolated catalytic domain. This observation suggests either that CDR-H3 (i) always interacted with the catalytic domain and simply lacked support from the original D1-V L for high affinity binding, or alternatively (ii) the CDR-H3 loop has been contorted by the neo-A12-V L to incorporate previously nonexistent catalytic domain binding. One of the key changes from the A12-V L was L94E > I in CDR-L3 (neutralization of negative charge) and L50T > D in CDR-L2 (gain of negative charge). Topologically, this charge migration flanks the CDR-H3 loop and could permit substantial macromolecular movement. CDR loop flexibility is well documented (34, 35) and RosettaAntibody models (28) support multiple D1 CDR-H3 conformations.
As many antibody paratopes are primarily supported by the V H domain, V L exchange is often used for affinity maturation. However, given that V L exchange was recently shown to modify a V Hbiased Her2 antibody to also bind VEGF (21) , this reselection technique clearly has considerable potential beyond monoantigen affinity maturation. Our work further demonstrates how manipulating initial selection conditions (e.g., by blocking undesired epitopes with SMIs or cofactors) can produce primary antibodies : AREG) and HeLa cells stably over expressing HB-EGF-Alkaline Phosphatase were used to assay cell-surface TACE activity. Each cell line was stimulated with PMA following a 1 h pretreatment with various concentrations of either D1(A12) human IgG1, N-TIMP-3, or control human plasma IgG. Soluble TACE products were quantified from conditioned medium by sandwich ELISA or alkaline phosphatase activity. D1(A12) IgG1 consistently inhibited cell-surface TACE activity around fivefold more potently than N-TIMP-3 (*). Cell-surface TACE inhibition directly correlates with the enzymatic data in B (i.e., Ã≈ †). Full IC 50 data can be found in Tables S1, S2 , and S3. All AE represent SD.
against directed epitopes. Secondary neo-variable domain selections using a modified antigen (e.g., no inhibitor/cofactor or a different antigen entirely) can then reexpose the initial antibody to new epitopes while retaining paratope elements from the primary antigen. This technique could be routinely used to produce antibodies against multidomain epitopes. For example, two-step phage display could theoretically produce antibodies against tertiary protein complexes (e.g., ligand-bound receptors), multiple local loops in membrane proteins (e.g., tetraspanins), and protein-nucleic acid complexes (transcription-factor DNA complexes). It is important to note that while our primary selection conditions promoted D1 scFv TACE non-catalytic-cleft binding (by blocking the TACE active site), the isolation of a purely V H -bias antibody was not encouraged by this method. Although many antibodies possess a V H -dominant paratope (particularly CDR-H3), our process relied on chance to provide an antibody suitable for V L exchange. Future efforts to develop a more predictable "V H then V L " selection approach could consider using a V H -only phage-display library for primary selection-followed by the cloning of selected V H genes into a naïve neo-V L library (complete scFv) for secondary selection. However, such an approach would suffer from instability issues associated with expressing human antibody variable domains in isolation (36) . A more stable alternative could be to employ a scFv library with multiple V H domains and a single constant V L domain for the primary selection. A subsequently selected V H domain could then be cloned into a naïve neo-V L library for secondary selection against a modified antigen.
In summary, we describe the bespoke development of a crossdomain inhibitory TACE antibody using two-step phage display.
By combining calculated selection conditions with antibody variable-domain exchange, we have produced a specifically potent ADAM ectodomain inhibitor. The resulting cross-domain human antibody D1(A12) provides a unique opportunity to study the individual pathological impact of TACE activity. Our approach is extendable to other multidomain macromolecules and provides a previously undescribed alternative to smallmolecule metalloprotease inhibition.
Materials and Methods
Recombinant human TACE ectodomain (Arg 215 -Arg 651 ) was biotinylated at a 1∶1 ratio using N-succinimidyl biotin (Invitrogen AL-01), checked for wildtype activity in a quenched-fluorescent peptide cleavage assay, and exposed to the naïve human scFv phage-display library of McCafferty (24) in the presence of 50 μM CT1746 (25) . Following two rounds of solution-phase selection, the eluted polyclonal scFv population was cloned into pSANG10-3F (37) and transformed into BL21(DE3) RIPL E. coli (Stratagene 230280). Individual scFv clones were isolated from E. coli periplasm and ELISA screened against immobilized recombinant TACE ectodomain in the absence of CT1746. Comprehensive screening details have been outlined previously (24, 26) . Following initial screening, selected anti-TACE scFv clones were expressed in 500 mL auto-induction (38) shake flask cultures and periplasmic fractions were purified by IMAC. Purified scFvs were screened for recombinant TACE inhibition in a quenched-fluorescent peptide assay and for cell-surface TACE inhibition in a PMA stimulated HB-EGF-alkaline phosphatase assay.
Detailed methods are described in SI Materials and Methods.
